BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
IPO Year: 1999
Exchange: NASDAQ
Website: biomarin.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2025 | $98.00 | Perform → Outperform | Oppenheimer |
| 11/15/2024 | $95.00 | Outperform | Wolfe Research |
| 10/30/2024 | Outperform → Mkt Perform | William Blair | |
| 10/10/2024 | $79.00 | Outperform | Raymond James |
| 8/20/2024 | $94.00 → $110.00 | Mkt Perform → Outperform | Bernstein |
| 5/17/2024 | $104.00 → $72.00 | Outperform → Neutral | Robert W. Baird |
| 5/14/2024 | $113.00 | Outperform | Evercore ISI |
| 11/15/2023 | $100.00 | Overweight | Wells Fargo |
| 10/23/2023 | $82.00 | Underperform → Mkt Perform | Bernstein |
| 9/28/2023 | Mkt Perform | Raymond James |
For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca
SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
Oppenheimer upgraded BioMarin Pharmaceutical from Perform to Outperform and set a new price target of $98.00
Wolfe Research initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $95.00
William Blair downgraded BioMarin Pharmaceutical from Outperform to Mkt Perform
Raymond James resumed coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $79.00
Bernstein upgraded BioMarin Pharmaceutical from Mkt Perform to Outperform and set a new price target of $110.00 from $94.00 previously
Robert W. Baird downgraded BioMarin Pharmaceutical from Outperform to Neutral and set a new price target of $72.00 from $104.00 previously
Evercore ISI initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $113.00
Wells Fargo initiated coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $100.00
Bernstein upgraded BioMarin Pharmaceutical from Underperform to Mkt Perform and set a new price target of $82.00
Raymond James initiated coverage of BioMarin Pharmaceutical with a rating of Mkt Perform
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
SC TO-C - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
SCHEDULE 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
DEFA14A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
DEF 14A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits SAN RAFAEL, Calif., May 12, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data from studies of VOXZOGO® (vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal condi
First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., May 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the first quarter ended March 31, 2025. "During the first quarter, we saw continued high demand for our innovative medicines resulting in strong revenue growth
SAN RAFAEL, Calif., April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144International Dial-in Number: 646-968-2525Conference Call ID: 4327591 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playba
Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone. Safety results were consistent with the known profile of the medicine. PALYNZIQ is the first and only enzyme therapy approved to treat adults with PKU. Detai
New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria SAN RAFAEL, Calif., March 20, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced positive new data from studies of VOXZOGO® (vosoritide) in children with achondroplasia and in ongoing clinical trials investigating other skeletal conditions, as well as PALYNZIQ® (pegvaliase-pqpz) in adults with phenylketonuria (PKU). The latest findings further validate the long-term benefit and established safety profiles of both medicines, which continue to play a pivotal role fo
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
SAN RAFAEL, Calif., Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. About BioMarinBioMarin is a global biotechnology company dedicated
SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025. Mr. Walbert led Horizon, a company that focused on medicines for rare diseases, from its founding in 2008 to acquisition by Amgen in 2023. Mr. Walbert is currently senior advisor, Amgen. Prior to Horizon, Mr. Walbert served as president and chief executive officer of IDM Pharma, w
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa
First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., May 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the first quarter ended March 31, 2025. "During the first quarter, we saw continued high demand for our innovative medicines resulting in strong revenue growth
SAN RAFAEL, Calif., April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144International Dial-in Number: 646-968-2525Conference Call ID: 4327591 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playba
Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025 4Q 2024 Total Revenues of $747 million (+16% Y/Y and +21% at Constant Currency Y/Y); FY 2024 Total Revenues of $2.85 billion (+18% Y/Y and +22% at Constant Currency Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., Feb. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2024.
SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 1878833 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number
Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion (+19% Y/Y and +23% at Constant Currency Y/Y) During the Quarter, Strong Demand Drove 54% Y/Y Revenue Growth for VOXZOGO® During the Quarter, Revenues from Enzyme Therapies Portfolio Increased 27% Y/Y Third Quarter 2024 GAAP Diluted Earnings Per Share (EPS) of $0.55 (+162% Y/Y); Year-to-date 2024 GAAP Diluted EPS of $1.56 (+103% Y/Y) Third Quarter 2024 Non-GAAP Diluted EPS of $0.91 (+98% Y/Y); Year-to-date 2024 Non-GAAP Diluted EPS of $2.60 (+63% Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., Oct. 29, 2024 /PRNe
SAN RAFAEL, Calif., Oct. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 29, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144International Dial-in Number: 646-968-2525Conference Call ID: 4980126 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Pla
NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin's leadership team provided an overview of the company's new corporate strategy to deliver sustained value creation and introduced longer-term Total Revenue and Non-GAAP Operating Margin guidance. A copy of the presentation and a replay of the webcast are available at investors.biomarin.com. "Over the last 9 months, we have undertaken the transformation of BioMarin's op
Second Quarter 2024 Total Revenues of $712 million (+20% Y/Y and +25% at Constant Currency Y/Y); First Half 2024 Total Revenues of $1.36 billion (+14% Y/Y and +19% at Constant Currency Y/Y) Second Quarter 2024 GAAP Diluted EPS of $0.55 (+90% Y/Y); First Half 2024 GAAP Diluted EPS of $1.01 (+80% Y/Y) Second Quarter 2024 Non-GAAP Diluted Earnings per Share (EPS) of $0.96 (+78% Y/Y); First Half 2024 Non-GAAP Diluted EPS of $1.67 (+46% Y/Y) Strong VOXZOGO® Demand in the Quarter Resulted in 73% Y/Y Increase in the Number of Children Receiving Treatment Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., Aug. 5, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:
SAN RAFAEL, Calif., July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 5, 2024, at 4:30 p.m. ET to discuss second quarter 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144International Dial-in Number: 646-968-2525Conference Call ID: 1816377 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playb
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025. Mr. Walbert led Horizon, a company that focused on medicines for rare diseases, from its founding in 2008 to acquisition by Amgen in 2023. Mr. Walbert is currently senior advisor, Amgen. Prior to Horizon, Mr. Walbert served as president and chief executive officer of IDM Pharma, w
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer. Ms. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
SAN RAFAEL, Calif., Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors effective January 1, 2022. "We are thrilled to have Mark join BioMarin's Board of Directors. He is a renowned leader in the biopharmaceutical industry, bringing deep operational, financial, business development and commercial experience to our exceptional board," said Jean-Jacques Bienaimé, Chairman and Chief
SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the life sciences industry, Maykin Ho, Ph.D., to its Board of Directors. "We are thrilled to welcome Maykin to BioMarin's Board of Directors. She brings a breadth and depth of experience in the healthcare industry and finance to an already exceptional board," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin. "Maykin brings an important perspective to support BioMarin's growth trajectory as we strive to address the unmet m